Gupta Mohit Dayal, Akkarappatty Cherian, Kunal Shekhar, Mp Girish, Bansal Ankit, Batra Vishal, Tyagi Sanjay
Department of Cardiology, Govind Ballabh Pant Institute of Post Graduate Medical Education and Research, Delhi, India.
Department of Medicine, Dr Moopens Medical College, Wayanad, Kerala, India.
Indian Heart J. 2024 Jan-Feb;76(1):67-70. doi: 10.1016/j.ihj.2024.01.017. Epub 2024 Feb 2.
Genetic polymorphism in endothelial Nitric Oxide Synthase (eNOS) are associated with occurrence of multiple cardiovascular diseases (CVDs).
This study included 300 young ST-segment elevation myocardial infarction (STEMI) patients and 300 healthy controls. STEMI patients were divided into two groups: premature coronary artery disease [CAD] (STEMI<40 years of age) and older STEMI (>40 years of age). Genetic polymorphisms in the eNOS gene (894G/T) was evaluated in both subjects and controls. Plasma levels of nitric oxide (NO) were estimated for both patients as well as controls.
Mean age of the study population was 49.7 ± 9.2 years with premature CAD being present in 58 (19.3 %) patients. No significant difference at genotypic (P = 0.589, odds ratio (OR) = 0.9, 95 % CI = 0.6-1.6) and allelic level (P = 0.173, OR = 1.2, 95 % CI = 0.9-1.4) was observed between STEMI patients and healthy controls. Genotype 894 TT had significantly higher frequency in STEMI patients >40 years (P = 0.047, OR: 2.5; 95 % CI = 1.0-6.0). No significant difference at genotypic (P = 0.279) and allelic level (P = 0.493) was observed between premature CAD (STEMI age <40 years) and healthy controls. NO levels (131 ± 59.6 μM vs 118.11 ± 49.96 μM; P = 0.001) was significantly higher in healthy controls as compared to STEMI patients >40 years of age (P= 0.001).
There was significant association of eNOS gene polymorphism Glu298Asp with STEMI patients > 40 years. However, this association was not observed in premature CAD patients. Lower levels of NO in STEMI patients >40 years suggests its potential role as a marker of CVD.
内皮型一氧化氮合酶（eNOS）基因多态性与多种心血管疾病（CVD）的发生有关。
本研究纳入300例年轻的ST段抬高型心肌梗死（STEMI）患者和300例健康对照者。STEMI患者分为两组：早发冠心病（CAD）（STEMI患者年龄<40岁）和老年STEMI患者（年龄>40岁）。对研究对象和对照者评估eNOS基因（894G/T）的基因多态性。测定患者和对照者血浆一氧化氮（NO）水平。
研究人群的平均年龄为49.7±9.2岁，58例（19.3%）患者患有早发CAD。STEMI患者与健康对照者在基因型水平（P=0.589，比值比（OR）=0.9，95%可信区间（CI）=0.6-1.6）和等位基因水平（P=0.173，OR=1.2，95%CI=0.9-1.4）未观察到显著差异。894TT基因型在年龄>40岁的STEMI患者中频率显著更高（P=0.047，OR：2.5；95%CI=1.0-6.0）。早发CAD（STEMI年龄<40岁）与健康对照者在基因型水平（P=0.279）和等位基因水平（P=0.493）未观察到显著差异。与年龄>40岁的STEMI患者相比，健康对照者的NO水平（131±59.6μM vs 118.11±49.96μM；P=0.001）显著更高（P=0.001）。
eNOS基因多态性Glu298Asp与年龄>40岁的STEMI患者显著相关。然而，在早发CAD患者中未观察到这种相关性。年龄>40岁的STEMI患者中较低的NO水平提示其作为CVD标志物的潜在作用。
